focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,812.50
Bid: 1,700.00
Ask: 1,820.00
Change: 0.00 (0.00%)
Spread: 120.00 (7.059%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks end in the red as recession fears mount

Fri, 23rd Jun 2023 16:58

(Alliance News) - Stocks in London closed lower on Friday as weak economic data and the prospect of global interests staying higher for longer put investors in a firmly risk-off mood.

"Up until last week, markets had been operating under the premise that rate hikes were coming to an end, however [US Federal Reserve Chair Jerome] Powell's press conference, along with a more hawkish narrative from the European Central Bank last week, and this week's bigger than expected rate hikes from the Bank of England and Norges Bank suggests higher rates are likely to be with us for a long time," said Michael Hewson, chief market analyst at CMC Markets.

"Consequently, markets are now repricing for just such a scenario, where growth is likely to slow considerably as recession risks increase."

The FTSE 100 index closed down 40.16 points, or 0.5% at 7,461.87 on Friday, ending the week 2.4% lower.

The FTSE 250 ended down 265.64 points, or 1.5%, at 18,062.33 and finished the past five days down 5.1%. The AIM All-Share closed down 6.37 points, or 0.8%, at 767.07 - finishing the week down 3.2%.

The Cboe UK 100 ended down 0.5% at 744.19, the Cboe UK 250 closed down 1.6% at 15,814.50, and the Cboe Small Companies ended down 0.6% at 12990.78.

Growth in the UK's private sector was slower than expected in June, according to preliminary survey data, as the gulf between manufacturing and services continued to widen.

The latest S&P Global/CIPS UK flash composite PMI fell to 52.8 points in June, from 54.0 in May. The market had been expecting only a slight decline to 53.6, according to FXStreet-cited consensus.

The flash services PMI fell to 53.7 from 55.2, lower compared to market forecasts of 54.8. Meanwhile, the contraction in manufacturing worsened, with the PMI slipping to 46.2 from 47.1, which was also below forecasts of 46.8.

The sluggish private sector growth has put the risk of an economic downturn in the UK at the forefront of investors' minds. Swissquote senior analyst Ipek Ozkardeskaya was more pessimistic: "At this point, it would be a miracle for Britain to avoid recession."

On Thursday, the Bank of England surprised with a chunkier-than-expected 50 basis point interest rate hike. It took bank rate to 5.00% from 4.50%.

The pound was quoted at USD1.2709 at the London equities close Friday, down from USD1.2741 at the close on Thursday.

Prior to the BoE's hike on Thursday, sterling had traded at USD1.2781 and had spiked as high as USD1.2830 in the immediate wake of the decision. Sterling has since lost all these gains.

In London, GSK was the top blue-chip performer at the close on Friday, finishing 5.0% higher.

The pharmaceutical company said it has reached a confidential settlement with James Goetz, a claimant in Zantac litigation. The case he filed in the California state court, which was set to begin in July, will now be dismissed.

Zantac is the subject of numerous lawsuits, which allegedly link the heartburn drug with cancer.

GSK said the settlement reflects its desire to avoid a protracted legal fight. It added that it does not admit any liability and will continue to "vigorously defend itself" in Zantac cases.

"News pharmaceutical giant GSK has settled a case in California alleging its Zantac heartburn medication caused cancer, while crucially admitting no liability, is not a full stop on the saga but is the latest punctuation point in what shareholders will hope is its final stanza," said AJ Bell's Hewson.

"Once the world's best-selling drug, there have been a series of lawsuits brought in the US implying a link between Zantac and cancer but, so far, GSK has been able to navigate its way through these choppy waters."

Haleon, which also has exposure to Zantac litigation, finished 0.6% higher.

Ocado ended as the FTSE 100's worst-performing stock on Friday. It finished 6.0% lower, slipping back from its 32% gain on Thursday which was driven by chatter that the online retailer and warehouse technology provider is the object of takeover interest.

In the FTSE 250, Volution was the index's best performer, finishing 2.90% higher after it announced it had completed its acquisition of designer, manufacturer and supplier of residential ventilation systems, I-Vent.

"We are delighted to have completed this earnings accretive transaction, and look forward to welcoming our new colleagues in I-Vent to the group. The acquisition gives the group access to fast-growing new markets in Slovenia and Croatia," said Chief Executive Ronnie George.

Elsewhere in London, EnQuest lost 6.4%.

The London-based oil and gas producer with assets in the UK and Malaysia's stock was under pressure as the price of a barrel of Brent oil fell to USD73.71 at the London equities close on Friday, from USD74.22 late Thursday.

"Pressure on oil prices in recent weeks has been largely supply-driven. Now, oil markets are struggling against an even more hawkish monetary policy backdrop than anticipated, which could hurt demand," explains SPI Asset Management's Stephen Innes.

On AIM, Hotel Chocolat plunged 17% after the high-street chocolatier warned it expects to swing to an underlying marginal pretax loss in its financial year ending July 2, defying market expectations of GBP300,000 in underlying pretax profit.

In financial 2024, it expects sales and underlying profit before tax to be lower than market expectations, due to weak consumer sentiment and continuing inflationary pressures.

In European equities on Friday, the CAC 40 in Paris ended down 0.6%, while the DAX 40 in Frankfurt ended down 1.0%.

Stocks in New York were lower at the London equities close, with the Dow Jones Industrial Average down 0.5%, the S&P 500 index down 0.7%, and the Nasdaq Composite down 1.0%.

The euro stood at USD1.0888 at the European equities close on Friday, sharply lower against USD1.0953 at the same time on Thursday. Against the yen, the dollar was trading at JPY143.73, higher compared to JPY142.86 late Thursday.

"The words from the chairman of the Fed, alongside the BoE's assertiveness, show that central banks aren't yet done with monetary tightening, in a dynamic that highlights the risks of an economic contraction. Against this background, there may be scope for further US dollar gains," said Ricardo Evangelista, senior analyst at ActivTrades.

Gold was quoted at USD1,922.24 an ounce, higher against USD1,913.60 at the close on Thursday.

In Monday's UK corporate calendar, there are half-year results from Rio Tinto and Carnival, as well as a trading statement from Associated British Foods.

The economic calendar next week has US house price data on Tuesday, US GDP figures on Thursday, and a flash inflation reading for the EU on Friday.

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more
30 Apr 2024 12:22

Sensodyne-maker Haleon to shut UK plant, 435 jobs to go

April 30 (Reuters) - Haleon, the world's largest standalone consumer healthcare firm, will shut its UK production site which makes Sensodyne toothpastes by 2026, leading to 435 job losses, a spokesperson said on Tuesday.

Read more
25 Apr 2024 15:53

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines.

Read more
24 Apr 2024 14:19

UK earnings, trading statements calendar - next 7 days

Thursday 25 April 
Aquila European Renewables PLCFull Year Results
Argo Blockchain PLCFull Year Results
AstraZeneca PLCQ1 Results
Barclays PLCQ1 Results
Checkit PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Destiny Pharma PLCFull Year Results
Dillistone Group PLCFull Year Results
Focusrite PLCHalf Year Results
Gem Diamonds LtdTrading Statement
Hikma Pharmaceuticals PLCTrading Statement
Hummingbird Resources PLCTrading Statement
Ibstock PLCTrading Statement
Inchcape PLCTrading Statement
J Sainsbury PLCFull Year Results
London Stock Exchange Group PLCQ1 Results
Persimmon PLCTrading Statement
Pinewood Technologies Group PLCFull Year Results
PPHE Hotel Group LtdTrading Statement
PureTech Health PLCFull Year Results
Relx PLCTrading Statement
Renewi PLCTrading Statement
Schroders PLCQ1 Results
Skillcast Group PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
Unilever PLCQ1 Results
WAG Payment Solutions PLCTrading Statement
Weir Group PLCTrading Statement
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Zinc Media Group PLCFull Year Results
Friday 26 April 
Facilities by ADF PLCFull Year Results
Kingspan Group PLCTrading Statement
Loungers PLCTrading Statement
NatWest Group PLC Q1 Results
Pearson PLCTrading Statement
Record PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Taylor Maritime Investments LtdTrading Statement
Monday 29 April 
Beazley PLCTrading Statement
Biome Technologies PLCFull Year Results
Christie Group PLCFull Year Results
Gresham House Energy Storage Fund PLCFull Year Results
Gresham Technologies PLCFull Year Results
Jadestone Energy PLCFull Year Results
Oxford BioMedica PLCFull Year Results
SpaceandPeople PLCFull Year Results
Tuesday 30 April 
Avacta Group PLCFull Year Results
Card Factory PLCFull Year Results
Capital & Regional PLCFull Year Results
Close Brothers Group PLCTrading Statement
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCHalf Year Results
Fadel Partners IncFull Year Results
Glencore PLCTrading Statement
Hargreaves Lansdown PLC Trading Statement
Howden Joinery PLCTrading Statement
HSBC Holdings PLCQ1 Results
Kelso Group PLCFull Year Results
Northcoders Group PLCFull Year Results
Phoenix Spree Deutschland LtdFull Year Results
RBG Holdings PLCFull Year Results
Rotork PLCTrading Statement
Safestore Holdings PLCHalf Year Results
Shield Therapeutics PLCFull Year Results
St James's Place PLCTrading Statement
Strip Tinning Holdings PLCFull Year Results
Whitbread PLCFull Year Results
Wednesday 1 May 
Computacenter PLCTrading Statement
GSK PLCQ1 Results
Haleon PLCTrading Statement
HSS Hire Group PLCFull Year Results
Intelligent Ultrasound Group PLCFull Year Results
Maintel Holdings PLCFull Year Results
Next PLCTrading Statement
Smith & Nephew PLCTrading Statement
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
24 Apr 2024 09:21

GSK's endometrial cancer drug receives FDA approval

(Sharecast News) - Drugmaker GSK said on Wednesday that the US Food and Drug Administration has accepted a supplemental Biologics License Application for Jemperli, its drug aimed at treating endometrial cancer.

Read more
24 Apr 2024 09:14

GSK's Jemperli with chemotherapy accepted for priority review by FDA

(Alliance News) - GSK PLC on Wednesday said that the US Food & Drug Administration has accepted a supplemental biologics licence application for Jemperli, when used in combination with chemotherapy.

Read more
17 Apr 2024 08:46

TOP NEWS: GSK hails data on Shingles vaccine and gonorrhoea treatment

(Alliance News) - GSK PLC on Wednesday reported new test data for its shingles vaccine and for a potential new oral treatment for a form of gonorrhoea.

Read more
17 Apr 2024 07:11

GSK posts promising results from gonorrhoea treatment trial

(Sharecast News) - GSK unveiled encouraging outcomes from a pivotal phase three trial on Wednesday, on the potential of gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea (GC), amid escalating resistance to current therapies.

Read more
16 Apr 2024 09:17

GSK meningococcal vaccine accepted by US FDA for review

(Sharecast News) - GSK announced on Tuesday that its five-in-one meningococcal ABCWY (MenABCWY) vaccine candidate had been accepted for regulatory review by the US Food and Drug Administration (FDA).

Read more
16 Apr 2024 08:59

GSK's latest meningitis vaccine accepted for review by US regulator

(Alliance News) - GSK PLC on Tuesday said it has made progress in the development of its newest candidate, which combines the strengths of two other vaccines in its portfolio into one bacteria-fighting inoculation.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.